SPROSpero Therapeutics, Inc.Small cap · $126.2M · FY ending 2025-12-31
$2.18+3.81% · 2026-07-13 · EOD
39/100 composite
A transparent blend of the four reads below — each opens into the tool it comes from. Not advice.Quality54
margins & F-ScoreValue48
P/E 14.5 · 30% of 12-mo rangeMomentum39
golden · price below 200-daySmart Money15
selling · 0 funds · 0P/5S insidersMixed trendGolden crossBelow 200-day
vs S&P 500-23.8%
6-mo excess Trailing performance1M -14.2%
3M -18.4%
6M -15.2%
YTD -7.2%
1Y -23.2%
P/E vs its last 12 months (our price history): 12.2 low → 19.9 high
Current price sits at the 30th percentile of that window — mid-range. We only compare against the price history we own (no paid multi-year multiples — nothing invented).
Piotroski F4/9
fundamental strength Altman ZDistress
bankruptcy zone ROIC = NOPAT ÷ (debt + equity − cash), using an effective tax rate of 3%. Annual figures from SEC XBRL.
Net selling0P / 5S insiders · 0 funds hold · 0 Congress buys
Recent insidersRajavelu Esther · See RemarksSELL$63,352
Keutzer Timothy · Chief Operating OfficerSELL$44,019
Rajavelu Esther · See RemarksSELL$207,484
Keutzer Timothy · Chief Operating OfficerSELL$101,175
Fhealth · 29/100
May need capitalGoing-concern flagGoing-concern warning — auditor flagged substantial doubt
- ●Going-concern warning Auditor flagged substantial doubt about the company continuing for the next 12 months — a raise is usually required.
- ●Bankruptcy-risk zone Altman Z-Score is in the distress zone (-0.01).
- ●One-sided insider selling 5 insider sales and no open-market buys in the recent window.
- filingMaterial agreement 8-K filed 2026-07-14 · source →
Educational tools — not financial advice. Fundamentals from SEC EDGAR (XBRL); prices are end-of-day (Databento). Scores are a transparent blend of the components shown, computed on our own data — a research aid, not a recommendation.